Novo Nordisk battling $3.9 billion TP adjustment on transfer of biopharmaceutical division

Denmark's largest listed company, Novo Nordisk, has been hit with transfer pricing adjustments of DKK 22 billion ($3.95 billion) by the Danish tax authority (SKAT) resulting in an increased tax bill of DKK 5.5 billion.